Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-dose pazopanib pharmacokinetic study
NL-OMON27697Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC) and soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoints: pazopanib Cmin and pazopanib AUC0-24h. Planned start Apr 2017; status: not yet recruiting.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON27697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27697.